Additionally, CDCP1, DUXAP8, SUCLG2P2, and MT1DP are recognized as prognostic indicators, offering insights into clinical outcomes and supporting tailored therapeutic approaches for CRC management. This evidence concerns the gene SUCLG2P2 and colorectal carcinoma.